Evidence map›Paper›PMID 29953423›Full record

ArticleTransplantation2018

Impact of Willingness to Accept Hepatitis C Seropositive Kidneys Among Hepatitis C RNA-Positive Waitlisted Patients.

Junichiro Sageshima, Christoph Troppmann, John P McVicar, Chandrasekar Santhanakrishnan, Angelo M de Mattos, Richard V Perez

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Junichiro SageshimaDepartment of Surgery, University of California Davis, Sacramento, CA.
Christoph TroppmannDepartment of Surgery, University of California Davis, Sacramento, CA.
John P McVicarDepartment of Surgery, University of California Davis, Sacramento, CA.
Chandrasekar SanthanakrishnanDepartment of Surgery, University of California Davis, Sacramento, CA.
Angelo M de MattosDepartment of Internal Medicine, University of California Davis, Sacramento, CA.
Richard V PerezDepartment of Surgery, University of California Davis, Sacramento, CA.
University of California, Davis · US

Funding

Using Technology to Enhance Cancer Communication and Improve Clinical OutcomesP50CA095817 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI GUSTAFSON, DAVID H · 2003 to 2012
$19.3M
NCI NIH HHS P50 CA095817
6 · The paper itself

Abstract

backgroundKidney transplantation from hepatitis C seropositive (HCV+) donors may benefit hepatitis C RNA-positive (RNA+) candidates, but it is unclear how the willingness to be listed for and accept such kidneys affects waitlist and transplant outcomes.

methodsIn a single-center retrospective analysis, HCV+ transplant candidates (N = 169) listed from March 2004 to February 2015 were evaluated. All RNA+ candidates were offered the option to be listed for HCV+ donors. RNA- candidates were listed only for HCV- donors.

resultsFifty-seven patients (51% of all RNA+ transplant candidates) willing to accept HCV+ donors were listed for both HCV+ and HCV- donor kidneys. During 6-year follow up, 43 (75%) of 57 patients accepting HCV+ versus 19 (35%) of 55 patients not accepting HCV+ received a deceased donor kidney transplant (P < 0.0001). Multivariable analysis demonstrated that willingness to be listed for and accept HCV+ kidneys was associated with receiving deceased donor kidney transplant (P = 0.0016). Fewer patients accepting HCV+ donors (7 [12%] vs 16 [29%]) were removed from the list due to death or deteriorated medical condition (P = 0.0117). Posttransplant patient and graft survival rates were not significantly different. Overall patient survival since the listing (combined waitlist and posttransplant survival) was similar among the groups.

conclusionsHCV RNA+ candidates had better access to transplantation and similar overall survival before the era of widespread use of direct-acting anti-HCV agents.

Indexed as

AllograftsDonor SelectionFemaleGraft SurvivalHepacivirusHepatitis CHumansKidneyKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPatient Acceptance of Health CareRetrospective StudiesRisk FactorsRNA, ViralRNA, Viral

Identifiers

PMID29953423
PMCPMC7228641
OpenAlexW2790615868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.